StockNews.AI
ICAD
StockNews.AI
174 days

Koios Medical and iCAD Partner to Expand AI-Powered, Multi-Modality Breast Cancer Detection Solutions at ECR 2025

1. iCAD partners with Koios Medical for a multi-modality breast cancer AI suite. 2. Integration enhances AI-driven diagnostics from screening to diagnosis. 3. Collaboration aims for improved clinical outcomes and workflow efficiency. 4. Growing demand for best-in-class AI solutions in breast imaging acknowledged. 5. Diverse applications of ultrasound for cancer detection highlighted.

9m saved
Insight
Article

FAQ

Why Bullish?

The partnership with Koios Medical enhances ICAD's product offerings, increasing market competitiveness. Historically, such collaborations have led to stock price increases due to boosted revenue prospects.

How important is it?

The partnership potentially enhances ICAD’s market share and technological capabilities, signaling positive future earnings. The impact of partnerships is critical in tech-centric healthcare, directly correlating with stock performance.

Why Long Term?

As AI adoption in healthcare continues to grow, ICAD's long-term prospects improve with this significant partnership. Previous cases show sustained growth post strategic partnerships, positively reflecting on stock performance over time.

Related Companies

KOIOQGENMDGL
February 26, 2025 14:46 ET  | Source: iCAD, Inc. NASHUA, N.H. and CHICAGO, Feb. 26, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered cancer detection solutions, and Koios Medical, a leader in AI-driven ultrasound cancer diagnosis, today announced a strategic reseller partnership to deliver a comprehensive, multi-modality AI suite for breast cancer detection. This collaboration integrates iCAD’s ProFound AI® Breast Health Suite for mammography with Koios SmartUltrasound™, providing radiologists with an AI-powered pathway from screening to diagnosis. “iCAD has long been a leader, the pioneer in AI for breast imaging. It is an honor to collaborate with a company with an unmatched track record of improving clinical outcomes for patients and a rich history of innovation,” said Chad McClennan, President & CEO of Koios Medical, Inc. The partnership reflects the rapidly growing adoption of best-in-class AI solutions across breast imaging facilities. “Our collaboration with iCAD is ultimately a customer-driven initiative. Breast imaging radiologists have long embraced innovation and are rapidly adopting best-of-breed AI solutions. Physicians seek accuracy, efficiency, and peace of mind. By offering an integrated ‘breast AI suite’ that includes both iCAD’s ProFound AI and Koios SmartUltrasound, we’re enabling a more comprehensive, AI-enhanced patient pathway. Streamlining AI acquisition and implementation across both mammography and breast ultrasound is a logical and necessary step forward,” said Chad McClennan, President & CEO of Koios Medical, Inc. Dana Brown, President and CEO of iCAD, added, “This partnership reinforces iCAD’s commitment to delivering innovative AI solutions that empower radiologists and improve patient outcomes. By integrating iCAD’s ProFound AI Breast Health Suite with Koios SmartUltrasound, we are providing clinicians with a more complete, end-to-end, AI-powered approach to breast cancer screening and detection that enhances workflow efficiency and diagnostic accuracy.” Koios SmartUltrasound is an AI-based software platform proven to accurately detect and diagnose both thyroid and breast cancers in ultrasound exams. Built using data sourced from a global network of partner sites, the technology aids physicians in quickly and accurately diagnosing disease, improving speed of interpretation, automating reporting, and reducing time to treatment, all while avoiding unnecessary surgical procedures. The increasing utilization of ultrasound in cancer detection, particularly for women with dense breast tissue, makes this innovation particularly relevant in today’s evolving healthcare landscape. Koios and iCAD will be attending ECR 2025 (Booth: AI-27 – Hall X1) from Wednesday, February 26 to March 2, 2025, in Vienna, Austria. To request a meeting or book a demo, please visit https://www.icadmed.com/about/news-events/upcoming-tradeshows-and-meetings/ecr-2025/ About Koios Medical:Koios Medical develops medical software to assist physicians interpreting ultrasound images and applies deep machine learning methods to the process of reaching an accurate diagnosis. The Koios DS platform uses advanced AI algorithms to assist in the early detection of disease while reducing recommendations for biopsy of benign tissue. Patented technology saves physicians time, helps improve patient outcomes, and reduces healthcare costs. Koios DS (decision support) is SmartUltrasound, presently focused on the breast and thyroid cancer diagnosis market. Women with dense breast tissue (over 40% in the US) often require an alternative to mammography for diagnosis. Ultrasound is a widely available and effective alternative to mammography using no ionizing radiation and is a standard of care for cancer diagnosis. Learn more about Koios at: koiosmedical.com. About iCAD, Inc.iCAD, Inc. (NASDAQ: ICAD) is a global leader on a mission to create a world where cancer can’t hide by providing clinically proven deep learning solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes. Headquartered in Nashua, N.H., USA, iCAD’s industry-leading ProFound Breast Health Suite provides AI-powered mammography analysis for breast cancer detection, density assessment and risk evaluation. Used by thousands of providers serving millions of patients, ProFound is available in over 50 countries. In the last five years alone, iCAD estimates reading more than 40 million mammograms worldwide, with nearly 30% being tomosynthesis. For more information, including the latest in regulatory clearances, please visit www.icadmed.com. Forward-Looking StatementsCertain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the expansion of access to the Company’s products, improvement of performance, acceleration of adoption, expected benefits of ProFound AI®, the benefits of the Company’s products, and future prospects for the Company’s technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company’s ability to achieve business and strategic objectives, the willingness of patients to undergo mammography screening, whether mammography screening will be treated as an essential procedure, whether ProFound AI will improve reading efficiency, improve specificity and sensitivity, reduce false positives and otherwise prove to be more beneficial for patients and clinicians, the impact of supply and manufacturing constraints or difficulties on our ability to fulfill our orders, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,” “seek,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at https://www.icadmed.com and on the SEC’s website at http://www.sec.gov. CONTACTS iCAD Media Inquiries:pr@icadmed.com iCAD Investor Inquiries:John Nesbett/Rosalyn ChristianIMS Investor Relationsicad@imsinvestorrelations.com Koios Inquiries: Media Contacts:Tonja Haugh thaugh@koiosmedical.com(716) 574-2165 

Related News